Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have received a consensus rating of “Buy” from the seven research firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $66.75.

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, December 17th.

Insider Transactions at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 15.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics in the 3rd quarter valued at about $42,000. Quest Partners LLC raised its holdings in shares of Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 3,579 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Arcturus Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Arcturus Therapeutics in the second quarter worth approximately $142,000. Finally, Point72 DIFC Ltd bought a new position in shares of Arcturus Therapeutics in the second quarter valued at $188,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Up 0.5 %

Shares of NASDAQ:ARCT opened at $17.02 on Wednesday. The firm has a 50-day simple moving average of $17.83 and a 200 day simple moving average of $20.71. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The company has a market cap of $461.02 million, a PE ratio of -7.67 and a beta of 2.62.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $41.67 million for the quarter, compared to analysts’ expectations of $49.16 million. During the same period in the prior year, the firm earned ($0.61) EPS. As a group, research analysts forecast that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.